文献速递新发突发、热带与寄生虫病

单胺氧化酶-A(MAO-A)低表达变异与间日疟复发风险增加相关

Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该研究回顾性分析205例间日疟患者,检测MAO-A与CYP2D6基因多态性,并在100例治疗第3天有血样的受试者中测定伯氨喹与羧基伯氨喹血药浓度,另在复发记录完整的受试者中分析酶变异与复发的关系。结果发现,同时携带MAO-A低表达等位基因和CYP2D6功能受损者羧基伯氨喹中位水平显著降低且复发显著增多;CYP2D6活性正常时MAO-A低表达与复发无关。

要点

  • MAO-A低表达等位基因合并CYP2D6功能受损者羧基伯氨喹中位水平显著降低。
  • 该联合基因型组间日疟复发显著增多。
  • CYP2D6活性正常时,MAO-A低表达状态与疟疾复发无关。

核心结论

  • MAO-A低表达变异可增强CYP2D6活性受损的负面影响,导致羧基伯氨喹代谢物水平降低和多次复发。
  • 研究结果支持羧基伯氨喹可能经CYP介导途径进一步代谢生成抗寄生虫生物活性代谢物的假说。

研究设计与样本

  • 回顾性分析205例间日疟患者样本,对MAO-A与CYP2D6基因多态性进行基因分型。
  • 在100例治疗第3天有血样的受试者中测定伯氨喹与羧基伯氨喹血药浓度。
  • 在复发记录完整的受试者组中分析酶变异与间日疟复发的关系。

主要发现

  • 携带MAO-A低表达等位基因合并CYP2D6功能受损的个体羧基伯氨喹中位水平显著降低。
  • 该组间日疟复发显著增多。
  • CYP2D6活性正常时,MAO-A低表达状态与疟疾复发无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Primaquine is essential for the radical cure of Plasmodium vivax malaria and must be metabolized into its bioactive metabolites. Accordingly, polymorphisms in primaquine-metabolizing enzymes can impact the treatment efficacy. This pioneering study explores the influence of monoamine oxidase-A (MAO-A) on primaquine metabolism and its impact on malaria relapses. METHODS: Samples from 205 patients with P. vivax malaria were retrospectively analysed by genotyping polymorphisms in MAO-A and cytochrome P450 2D6 (CYP2D6) genes. We measured the primaquine and carboxyprimaquine blood levels in 100 subjects for whom blood samples were available on the third day of treatment. We also examined the relationship between the enzyme variants and P. vivax malaria relapses in a group of subjects with well-documented relapses. RESULTS: The median carboxyprimaquine level was significantly reduced in individuals carrying low-expression MAO-A alleles plus impaired CYP2D6. In addition, this group experienced significantly more P. vivax relapses. The low-expression MAO-A status was not associated with malaria relapses when CYP2D6 had normal activity. This suggests that the putative carboxyprimaquine contribution is irrelevant when the CYP2D6 pathway is fully active. CONCLUSIONS: We found evidence that the low-expression MAO-A variants can potentiate the negative impact of impaired CYP2D6 activity, resulting in lower levels of carboxyprimaquine metabolite and multiple relapses. The findings support the hypothesis that carboxyprimaquine may be further metabolized through CYP-mediated pathways generating bioactive metabolites that act against the parasite.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Puça MCSB, Rodrigues DF, Salazar YEAR, et al. Monoamine oxidase-A (MAO-A) low-expression variants and increased risk of Plasmodium vivax malaria relapses. J Antimicrob Chemother. 2024. PMID: 38870082. doi:10.1093/jac/dkae196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。